# Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

> **NCT03693339** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Cancer
- Lung Cancer Metastatic
- MET Gene Mutation

## Interventions

- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT03693339
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-30
- **Primary completion:** 2020-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693339, "Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03693339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*